Feb 15th 2013 - Edison Investment Research today published a report on E Therapeutics (ETX.L, LSE:ETX, LON:ETX) entitled "Funded Through To 2017". In summary, the report says:
e-Therapeutics is raising £39m (net) primarily to fund the development of ETS2101, its lead drug candidate, through to complete Phase II trials in glioma. The new funds will also allow a Phase Ib/II trial programme in additional cancer indications to be implemented. Positive results would provide major value inflection points and facilitate an out-licensing deal. Parts of the proceeds are earmarked to bolster new drug discovery activities using the proprietary network pharmacology technology platform. The pro forma £48m net cash suggests the company is funded through to 2017.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »